When liver functions and reserve are normal, pegvisomant-mediated blockade of GH/GHR signaling results in decreased serum concentrations of total and free IGF-I, a growth-promoting cytokine in acromegaly and a survival-promoting cytokine for cancer cells, in humans (39). Here, GHR is linked to cancer.